1051 ET - There will be a debate around how conservative Doximity's guidance is until the company's typical upselling season kicks off in August, JPMorgan analysts say in a research note. At that point, Doximity will have better clarity into how the budgets of its pharmaceutical clients are shaping up, the analysts say. As of right now, the company's outlook assumes some weakness in cross-selling and upselling, they say. But management says it hasn't seen any indications yet of its market slowing, and that Doximity faces less risk than it used to now that just under 70% of the year's revenue is already under contract, the analysts say. (dean.seal@wsj.com)

(END) Dow Jones Newswires

May 16, 2025 10:51 ET (14:51 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.